News

Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea. Dubbed the “Super Plant,” the new, multi-story 238,000-square-meter construction will be the world’s largest biopharmaceutical manufacturing facility of its kind boasting 256,000 liters total manufacturing capacity. In...

In its endeavour to further boost up the supplies of COVID-19 doses once they are available for use, the European Commission has approved a contract under the EU Vaccines Strategy, a sixth of the lot with Moderna, the American...

The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life science and healthcare R&D, has launched a free to use UXLS (User Experience in Life Sciences) maturity model. The model will help companies...

Bharat Biotech, during its phase 1 trials, experienced an adverse event in a volunteer that it did not promptly admit to the public. As per a statement from the vaccine maker, the event was reported in a timely manner...

Preliminary results from an interim analysis of clinical trials of the ChAdOx1 nCoV-19 candidate show the vaccine is on average 70.4% effective at preventing Covid-19. Data was taken from two dosing regimes, which show that the vaccine is 90%...

A leading Chinese vaccine developer has applied for authorization to bring its Covid-19 shot to the market, seeking to get a jump on Western rivals as the race for a working inoculation against the virus enters the final stretch. China...

Vaccines developed by Chinese pharmaceutical company Sinopharm Group have now been used on nearly one million people, with no serious adverse reactions reported, and only a few people reporting mild symptoms, Sinopharm Chairman Liu Jingzhen told Chinese media. The vaccines'...